These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 24662711)

  • 1. Bacteria expressed hepatitis E virus capsid proteins maintain virion-like epitopes.
    Wei M; Zhang X; Yu H; Tang ZM; Wang K; Li Z; Zheng Z; Li S; Zhang J; Xia N; Zhao Q
    Vaccine; 2014 May; 32(24):2859-65. PubMed ID: 24662711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin(®).
    Zhang X; Wei M; Pan H; Lin Z; Wang K; Weng Z; Zhu Y; Xin L; Zhang J; Li S; Xia N; Zhao Q
    Vaccine; 2014 Jul; 32(32):4039-50. PubMed ID: 24892250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Selection of a peptide mimic the neutralization epitope of hepatitis E virus with phage peptide display technology].
    Gu Y; Zhang J; Wang YB; Li SW; Yang HJ; Luo WX; Xia NS
    Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):680-5. PubMed ID: 15971579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-time stability of a hepatitis E vaccine (Hecolin®) demonstrated with potency assays and multifaceted physicochemical methods.
    Zhang X; Wei M; Sun G; Wang X; Li M; Lin Z; Li Z; Li Y; Fang M; Zhang J; Li S; Xia N; Zhao Q
    Vaccine; 2016 Nov; 34(48):5871-5877. PubMed ID: 27793484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of capsid protein (p495) of hepatitis E virus expressed in Escherichia coli and assembling into particles in vitro.
    Zheng M; Jiang J; Zhang X; Wang N; Wang K; Li Q; Li T; Lin Q; Wang Y; Yu H; Gu Y; Zhang J; Li S; Xia N
    Vaccine; 2018 Apr; 36(16):2104-2111. PubMed ID: 29544686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of hepatitis E virus neutralization sites using monoclonal antibodies directed against a virus capsid protein.
    Zhang J; Gu Y; Ge SX; Li SW; He ZQ; Huang GY; Zhuang H; Ng MH; Xia NS
    Vaccine; 2005 Apr; 23(22):2881-92. PubMed ID: 15780737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation in yeast and antigenic characterization of hepatitis E virus capsid protein virus-like particles.
    Simanavicius M; Tamosiunas PL; Petraityte-Burneikiene R; Johne R; Ulrich RG; Zvirbliene A; Kucinskaite-Kodze I
    Appl Microbiol Biotechnol; 2018 Jan; 102(1):185-198. PubMed ID: 29143081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant Hepatitis E virus like particles can function as RNA nanocarriers.
    Panda SK; Kapur N; Paliwal D; Durgapal H
    J Nanobiotechnology; 2015 Jun; 13():44. PubMed ID: 26104584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity difference between two hepatitis E vaccines derived from genotype 1 and 4.
    Wen J; Behloul N; Dai X; Dong C; Liang J; Zhang M; Shi C; Meng J
    Antiviral Res; 2016 Apr; 128():36-42. PubMed ID: 26850829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production and Characterization of Self-Assembled Virus-like Particles Comprising Capsid Proteins from Genotypes 3 and 4 Hepatitis E Virus (HEV) and Rabbit HEV Expressed in
    Kobayashi T; Takahashi M; Ohta S; Hoshino Y; Yamada K; Jirintai S; Primadharsini PP; Nagashima S; Murata K; Okamoto H
    Viruses; 2024 Aug; 16(9):. PubMed ID: 39339876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved characteristics and protective efficacy in an animal model of E. coli-derived recombinant double-layered rotavirus virus-like particles.
    Li T; Lin H; Zhang Y; Li M; Wang D; Che Y; Zhu Y; Li S; Zhang J; Ge S; Zhao Q; Xia N
    Vaccine; 2014 Apr; 32(17):1921-31. PubMed ID: 24530406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and epitope mapping of monoclonal antibodies raised against rat hepatitis E virus capsid protein: An evaluation of their neutralizing activity in a cell culture system.
    Kobayashi T; Takahashi M; Tanggis ; Mulyanto ; Jirintai S; Nagashima S; Nishizawa T; Okamoto H
    J Virol Methods; 2016 Jul; 233():78-88. PubMed ID: 26992654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in the Production of Virus-Like Particles for Vaccination against Hepatitis E Virus.
    Mazalovska M; Kouokam JC
    Viruses; 2020 Jul; 12(8):. PubMed ID: 32751441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comprehensive Study of Neutralizing Antigenic Sites on the Hepatitis E Virus (HEV) Capsid by Constructing, Clustering, and Characterizing a Tool Box.
    Zhao M; Li XJ; Tang ZM; Yang F; Wang SL; Cai W; Zhang K; Xia NS; Zheng ZZ
    J Biol Chem; 2015 Aug; 290(32):19910-22. PubMed ID: 26085097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimodal investigation of rat hepatitis E virus antigenicity: Implications for infection, diagnostics, and vaccine efficacy.
    Sridhar S; Situ J; Cai JP; Yip CC; Wu S; Zhang AJ; Wen L; Chew NF; Chan WM; Poon RW; Chan JF; Tsang DN; Chen H; Xia NS; Yuen KY
    J Hepatol; 2021 Jun; 74(6):1315-1324. PubMed ID: 33845058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of immunodominant and conformational epitopes in the capsid protein of hepatitis E virus by using monoclonal antibodies.
    Riddell MA; Li F; Anderson DA
    J Virol; 2000 Sep; 74(17):8011-7. PubMed ID: 10933710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of antibody response against hepatitis E virus (HEV) with recombinant human papillomavirus pseudoviruses expressing truncated HEV capsid proteins in mice.
    Renoux VM; Fleury MJ; Bousarghin L; Gaitan J; Sizaret PY; Touzé A; Coursaget P
    Vaccine; 2008 Dec; 26(51):6602-7. PubMed ID: 18835319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional epitopes on hepatitis E virions and recombinant capsids are highly conformation-dependent.
    He B; Zhang Z; Zhang X; Tang Z; Liu C; Zheng Z; Li S; Zhang J; Xia N; Zhao Q
    Hum Vaccin Immunother; 2020 Jul; 16(7):1554-1564. PubMed ID: 31995442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis E vaccine candidate harboring a non-particulate immunogen of E2 fused with CRM197 fragment A.
    Wang K; Zhou L; Zhang X; Song C; Chen T; Li J; Zheng M; Wang Y; Zheng Q; Zheng Z; Yu H; Wu T; Gu Y; Zhang J; Zhao Q; Li S; Xia N
    Antiviral Res; 2019 Apr; 164():154-161. PubMed ID: 30802475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production of monoclonal antibodies against hepatitis E virus capsid protein and evaluation of their neutralizing activity in a cell culture system.
    Takahashi M; Hoshino Y; Tanaka T; Takahashi H; Nishizawa T; Okamoto H
    Arch Virol; 2008; 153(4):657-66. PubMed ID: 18266052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.